Compass Psilocybin Therapy Achieves Key Phase 3 Success in Depression Treatment
TL;DR
Compass Pathways announced positive results from the largest-ever Phase 3 study of psilocybin for treatment-resistant depression, showing a significant reduction in depression scores, though investor response was muted due to the effect size not being larger. The study met its primary endpoint, and safety data was favorable, marking a key step toward potential approval.
- Compass psilocybin therapy shown to be effective in largest-ever study in depression STAT
- Compass Pathways’ Psilocybin Clears First Phase 3 Hurdle Psychedelic Alpha
- Compass’s Psychedelic Drug to Treat Depression Meets Goal in Trial Yahoo Finance
- Compass points to psychedelic therapy's phase 3 depression win, but investors unimpressed Fierce Biotech
- Despite topline trial success, Compass going in wrong direction The Pharma Letter
Want the full story? Read the original reporting
Read on STAT